Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

212

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
Sickle Cell DiseaseIron OverloadHemolytic Anemia
Interventions
DRUG

Deferasirox (ICL670)

Deferasirox was provided in 125 mg, 250 mg, and 500 mg dispersible tablets and was administered orally at an initial dose of 20 mg/kg/day.

DRUG

Deferoxamine (DFO)

Deferoxamine was supplied in vials of 500 mg and 2000 mg administered subcutaneously for a weekly dose of 175 mg/kg.

Trial Locations (59)

10021

Weill Medical College of Cornell University, New York

10032

Columbia University, New York

11203

SUNY Downstate Medical Center, Brooklyn

11215

New York Methodist Hospital, Brooklyn

15213

Children's Hospital of Pittsburgh, Pittsburgh

15232

Hillman Cancer Center, Pittsburgh

19106

Pennsylvania Oncology/Hematology, Philadelphia

19107

Jefferson University, Philadelphia

20010

Children's National Medical Center, Washington D.C.

20059

Howard University Hospital, Washington D.C.

23507

Children's Hospital of the King's Daughter, Norfolk

28232

Carolinas Medical Transplant Center, Charlotte

29150

Santee Hematology/Oncology, Sumter

29203

Liberty Hematology Oncology Center, Columbia

Palmetto Health Clinical Trials, Columbia

30303

Emory University School of Medicine, Atlanta

30342

Children's Healthcare of Atlanta at Scottish Rite, Atlanta

31403

Backus Children's Hospital, Savannah

33155

Miami Children's Hospital, Miami

33612

H. Lee Muffit Cancer Center and Research Institute/James A. Haley Veterans Hospital, Tampa

35233

University of Alabama Pediatric Hematology/Oncology, Birmingham

35294

University of Alabama Medical center, Birmingham

36604

University of South Alabama Medical Center, Mobile

36617

University of South Alabama, Mobile

38105

St. Jude's Children Research Hospital, Memphis

45219

University of Cincinnati, Cincinnati

46202

Pediatric Sickle Cell Program/James Whitcomb Riley Hospital for Children, Indianapolis

48201

Karmanos Cancer Institute, Detroit

60612

University of Illinois at Chicago, Chicago

63110

Washington University School of Medicine, St Louis

70112

Tulane University Sickle Cell Center, New Orleans

70118

Children's Hospital, New Orleans

70808

St. Jude Children's Hospital Affiliate, Baton Rouge

71130

LSU Health Sciences Center/Carroll W. Feist Professor of Cancer Research, Shreveport

72764

Children's Hospital Medical Center, Cincinnati

73104

The University of Oklahoma, Oklahoma City

76508

Scott and White Memorial Hospital & Clinics, Temple

92354

Loma Linda University Medical Center, Loma Linda

94609

Children's Hospital Oakland, Oakland

20010-2970

Center for Cancer and Blood Disorders, Washington D.C.

33607-6387

Tampa Children's Hospital at St Joseph's, Tampa

Tampa Children's Hospital at St. Joseph's, Tampa

30912-3128

Adult Sickle Cell Clinic, Augusta

60614-3394

Children's Memorial Hospital, Chicago

02115

Brigham and Woman's Hospital/Harvard Medical School, Boston

Children's Hospital Boston, Boston

Children's Hospital, Boston

48109-0238

University of Michigan, Ann Arbor

10467-2490

Sickle Cell Center, Montefiore Hospital, The Bronx

19104-4399

Children's Hospital of Philadelphia, Philadelphia

19134-1095

Drexel University College of Medicine, Philadelphia

38105-2794

St Jude's Children's Research Hospital, Memphis

76104-2724

Cooks Children's Hospital, Fort Worth

77030-2399

Texas Children's Hospital/Baylor College of Medicine, Houston

23298-0306

Medical College of Virginia, Richmond

23298-0646

Virginia Commonwealth University, Richmond

T6G 2H7

University of Alberta, Edmonton

K1H 8L6

The Ottawa Hospital, Ottawa

H3T 1C5

Hopital Ste-Justine, Montreal

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY